Oligodendroglioma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Xynomic Pharma, Oblato, Incyte Crp, SpringWorks Therapeutics

Oligodendroglioma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Xynomic Pharma, Oblato, Incyte Crp, SpringWorks Therapeutics
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Oligodendroglioma pipeline constitutes 10+ key companies continuously working towards developing 10+ Oligodendroglioma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Oligodendroglioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Oligodendroglioma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Oligodendroglioma Market.


Some of the key takeaways from the Oligodendroglioma Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Oligodendroglioma treatment therapies with a considerable amount of success over the years. 
  • Oligodendroglioma companies working in the treatment market are Xynomic Pharmaceuticals, Inc., Oblato, Inc., SpringWorks Therapeutics, Incyte Corporation, and others, are developing therapies for the Oligodendroglioma treatment 
  • Emerging Oligodendroglioma therapies in the different phases of clinical trials are- PCI-24781, OKN-007, Mirdametinib, Pemigatinib, Retifanlimab, and others are expected to have a significant impact on the Oligodendroglioma market in the coming years.   
  • In January 2024, AbbVie is currently advancing the clinical development of BBV-706, with the drug currently in Phase I trials targeting Oligodendroglioma. GlobalData notes that there is insufficient historical data for Phase I drugs addressing Oligodendroglioma to establish a benchmark PTSR (Patient and Treatment Satisfaction Rate) for this specific phase.


Oligodendroglioma Overview

Oligodendroglioma (OG) originates from oligodendrocytes, glial cells responsible for producing myelin—a fatty white substance that covers nerves, facilitating faster transmission of signals (impulses). Typically, oligodendrogliomas are located in the frontal lobe of the cerebrum.


Get a Free Sample PDF Report to know more about Oligodendroglioma Pipeline Therapeutic Assessment-



Emerging Oligodendroglioma Drugs Under Different Phases of Clinical Development Include:

  • PCI-24781: Xynomic Pharmaceuticals, Inc.
  • OKN-007: Oblato, Inc.
  • Mirdametinib: SpringWorks Therapeutics
  • Pemigatinib: Incyte Corporation
  • Retifanlimab: Incyte Corporation


Oligodendroglioma Route of Administration

Oligodendroglioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous


Oligodendroglioma Molecule Type

Oligodendroglioma Products have been categorized under various Molecule types, such as

  • Gene Therapy
  • Small molecule
  • Antibody


Oligodendroglioma Pipeline Therapeutics Assessment

  • Oligodendroglioma Assessment by Product Type
  • Oligodendroglioma By Stage and Product Type
  • Oligodendroglioma Assessment by Route of Administration
  • Oligodendroglioma By Stage and Route of Administration
  • Oligodendroglioma Assessment by Molecule Type
  • Oligodendroglioma by Stage and Molecule Type


DelveInsight’s Oligodendroglioma Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Oligodendroglioma product details are provided in the report. Download the Oligodendroglioma pipeline report to learn more about the emerging Oligodendroglioma therapies


Some of the key companies in the Oligodendroglioma Therapeutics Market include:

Key companies developing therapies for Oligodendroglioma are – AngioChem Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Cavion LLC, Celldex Therapeutics Inc, Eli Lilly and Co, F. Hoffmann-La Roche Ltd, Immatics Biotechnologies GmbH, Ipsen SA, Leadiant Biosciences Inc, Millennium Pharmaceuticals Inc, Northwest Biotherapeutics Inc, Novartis AG, Pfizer Inc, Tocagen Inc, and others.


Oligodendroglioma Pipeline Analysis:

The Oligodendroglioma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Oligodendroglioma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oligodendroglioma Treatment.
  • Oligodendroglioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Oligodendroglioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oligodendroglioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Oligodendroglioma drugs and therapies


Oligodendroglioma Pipeline Market Drivers

  • Rising incidence of the Oligodendroglioma, advancements in pharmacology and molecular biology to promote drug development are some of the important factors that are fueling the Oligodendroglioma Market.


Oligodendroglioma Pipeline Market Barriers

  • However, high cost associated with the management, side effects associated with the treatment and other factors are creating obstacles in the Oligodendroglioma Market growth.


Scope of Oligodendroglioma Pipeline Drug Insight    

  • Coverage: Global
  • Key Oligodendroglioma Companies: Xynomic Pharmaceuticals, Inc., Oblato, Inc., SpringWorks Therapeutics, Incyte Corporation, and others
  • Key Oligodendroglioma Therapies: PCI-24781, OKN-007, Mirdametinib, Pemigatinib, Retifanlimab, and others
  • Oligodendroglioma Therapeutic Assessment: Oligodendroglioma current marketed and Oligodendroglioma emerging therapies
  • Oligodendroglioma Market Dynamics: Oligodendroglioma market drivers and Oligodendroglioma market barriers 


Request for Sample PDF Report for Oligodendroglioma Pipeline Assessment and clinical trials


Table of Contents

1. Oligodendroglioma Report Introduction

2. Oligodendroglioma Executive Summary

3. Oligodendroglioma Overview

4. Oligodendroglioma- Analytical Perspective In-depth Commercial Assessment

5. Oligodendroglioma Pipeline Therapeutics

6. Oligodendroglioma Late Stage Products (Phase II/III)

7. Oligodendroglioma Mid Stage Products (Phase II)

8. Oligodendroglioma Early Stage Products (Phase I)

9. Oligodendroglioma Preclinical Stage Products

10. Oligodendroglioma Therapeutics Assessment

11. Oligodendroglioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Oligodendroglioma Key Companies

14. Oligodendroglioma Key Products

15. Oligodendroglioma Unmet Needs

16 . Oligodendroglioma Market Drivers and Barriers

17. Oligodendroglioma Future Perspectives and Conclusion

18. Oligodendroglioma Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services